期刊
CANCER DISCOVERY
卷 11, 期 11, 页码 2674-2676出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-21-1046
关键词
-
类别
The combination of CAR T cells with Pembrolizumab demonstrates efficacy in cold solid tumors with low genomic heterogeneity, while Atezolizumab-Bevacizumab combination offers a straightforward approach of antiangiogenics and immunotherapy for orphan diseases.
Chimeric antigen receptor (CAR) T cells targeting mesothelin plus pembrolizumab, and atezolizumab plus bevacizumab, have recently shown clinical efficacy in phase I trials in malignant pleural and peritoneal mesothelioma. Despite being tested in a highly selected patient population and requiring a complex engineering that can hardly be upscaled, CAR T cells combined with pembrolizumab bring the first proof of efficacy in cold solid tumors with low genomic heterogeneity, while atezolizumab-bevacizumab offers an easy-to-use combination of antiangiogenics and immunotherapy in an orphan disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据